Skip to main content
Premium Trial:

Request an Annual Quote

Agendia Raises Double Digit $ Millions in Series A Round for Microarray-Based Cancer Tests

This story has been updated from an earlier version to include more precise funding information from Agendia.


NEW YORK, GenomeWeb News (March 30) - Dutch cancer diagnostics company Agendia has raised "double digit" millions of dollars in a Series A financing round, the company told GenomeWeb News today.


Agendia will use the funding to market its microarray-based breast cancer test, which it launched earlier this year, and to develop similar gene expression-based tests for other cancers.


Investors included Gilde Investment Management, which led the round, as well as Global Life Science Ventures and Axa Private Equity Funds.


Agendia, based in Amsterdam, the Netherlands, was founded in 2003 by scientists from the Netherlands Cancer Institute who developed a microarray-based test to predict the aggressiveness of breast cancer tumors.


Bas van der Baan, Agendia's director of business development, told GenomeWeb News that the company is seeking to in-license additional expression profiles for cancer and other diseases. Also, Agendia plans to launch new expression-based tests within 12 months. 

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.